Related Experiment Video

Updated: May 23, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Novel therapeutic strategies for AML in 2012

Martin S Tallman1

  • 1Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, 1275 York Ave. Box 380, New York, NY 10065, USA. Tallmanm@mskcc.org

Hematology (Amsterdam, Netherlands)
|April 18, 2012
PubMed

Insights

Therapeutic advances in acute myeloid leukemia (AML) have lagged behind molecular understanding. Current treatments like chemotherapy and stem cell transplants offer some success, but novel targeted therapies are needed.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Significant progress in understanding acute myeloid leukemia (AML) molecular pathogenesis and prognostic factors over four decades.
  • Therapeutic advancements in AML have been considerably slower compared to molecular insights.
  • The standard induction therapy (anthracycline and cytarabine) has seen limited major changes, with advances primarily benefiting younger patients or those with favorable biology.

Purpose of the Study:

  • To review the progress in acute myeloid leukemia (AML) therapy.
  • To highlight the limitations of current treatment strategies.
  • To emphasize the potential of novel molecularly targeted therapies.

Main Methods:

  • Review of established and emerging treatment modalities for acute myeloid leukemia (AML).
  • Analysis of the impact of dose intensification and allogeneic hematopoietic cell transplantation on patient outcomes.
  • Exploration of research into novel drugs targeting specific molecular pathways in AML.

Main Results:

  • Intensification of post-remission cytarabine improves cure rates in patients achieving first complete remission (CR).
  • Daunorubicin dose intensification demonstrates improved outcomes in younger AML patients.
  • Allogeneic hematopoietic cell transplantation is a viable strategy for many patients in first CR.

Conclusions:

  • Despite progress in understanding AML, therapeutic advancements remain limited.
  • Current effective strategies include post-remission chemotherapy intensification, dose-adjusted daunorubicin, and allogeneic stem cell transplantation.
  • Development of novel drugs targeting specific molecular pathways represents a promising frontier for future AML treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...